KREHER NERISSA 4

What Happened

• Nerissa Kreher, a director of Xeris Biopharma (ticker: XERS), was granted equity on 2026-07-01: 33,582 restricted stock units (RSUs) at $0.00 and 37,910 stock options with an $8.00 exercise price (reported value $303,280). These grants are awards/compensation rather than open‑market purchases or sales.

Key Details

• Transaction date: 2026-07-01; Form 4 filed 2026-07-02 (filed promptly the next day).
• RSUs: 33,582 units, reported acquisition value $0.00 (F1). Each RSU converts to one share upon vesting.
• Options: 37,910 stock options with $8.00 exercise price, reported value $303,280 (F2).
• Vesting: Both the RSUs and options vest in equal annual installments over three years, contingent on continued service on the Board.
• Shares owned after transaction: Not disclosed in this filing.
• Filing status: Not marked late; appears timely (filed the business day after the report date).
• Remark in filing: Director (board compensation).

Context

• These grants are typical director compensation (awards), which are routine and do not by themselves signal a buy or sell intent. The options are not exercised or sold here; they are grants that will only convert to an ownership stake if vested and (for options) exercised later.